VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates

Vertex Pharmaceuticals Incorporated (VRTX) announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for the treatment of type 1 diabetes (T1D). Zimislecel is designed for the transplantation of islet cells alone, using immunosuppression to protect the implanted cells. The candidate is in pivotal late-stage development for treating patients with T1D with severe hypoglycemic events (SHEs) and impaired awareness of hyp ...